Suzuki 2020.

Study characteristics
Methods	Study design: Parallel‐group randomised trials Duration of trial: August 2014 to April 2017 Duration of follow‐up: 30 days Country of origin: Japan
Participants	Baseline characteristics Number randomised: 254 participants Number analysed: 251 participants Intervention: MBP+oAB Number of participants [n]: 125 Age [years; mean (SD)]: 69 (12) Gender [male/female; n]: 66/61 Control: nBP Number of participants [n]: 126 Age [years, mean (SD)]: 70 (9) Gender [male/female; n]: 68/59 Inclusion criteria  Quote: "Diagnosis of primary colon cancer, age of 20 to 85 years, and Eastern Cooperative Oncology Group performance status of 0 or 1." Exclusion criteria Quote: "Patients with a stoma, patients in whom conventional preoperative MBP could not be performed because of stenosis or obstruction, patients with a preoperative diagnosis of stage 4 disease, patients with an American Society of Anesthesi ologists score of ≥4, and patients who were scheduled to simultaneously undergo resection of other organs were excluded from the study" Baseline imbalances Quote: "There was no significant difference between the groups in age, sex, or hemoglobin or albumin levels in peripheral blood before surgery, the presence or absence of diabetes mel litus, American Society of Anesthesiologists score, tumor location, or histological stage. There was also no significant difference between the groups in operation time, bleeding volume, or the presence or absence of blood transfusion."
Interventions	Comparison Intervention: MBP+oAB Control: nBP MBP Agent(s): 1) sodium picosulfate and 2) polyethylene glycol‐electrolyte sodium Dose per administration: 1) 10 ml; 2) 2000 ml Time(s) of intake: 1) 2 days before the surgery: 2) on the morning of the day before surgery Route: oral Concomitant medications: ‐ oAB Agent(s): kanamycin sulfate and metronidazole Dose per administration: 500 mg each Time(s) of intake: both at 1:00, 2:00, and 11:00 PM on the day before surgery Route: oral Concomitant medications: ‐ Perioperative intravenous antibiotic prophylaxis Agent(s): flomoxef Dose per administration: 1000 mg Time(s) of intake: "Given as a continuous intravenous infusion starting 1 h before surgery. If the operation time exceeded 3 h, 1 g of flomoxef was additionally given" Adherence to regimen: ‐
Outcomes	Outcomes sought in review and reported in trial SSI (superficial and organ/space) Anastomotic leakage Length of hospital stay Outcomes sought but not reported in trial Deep SSI Mortality Postoperative complications (mild D/C I + II or severe D/C III + IV) Length of hospital stay Incidence of postoperative ileus Side effects of Interventions Outcomes reported in trial but not used in review Other infectious complications Small bowel obstruction
Notes	Source of funding: ‐ Conflicts of interest:Quote:  "The authors declare that they have no conflicts of interest to disclose" Ethics approval:Quote:  "Ethical approval of Institutional Review Board of Tokai Uni versity was obtained" Informed consent: All patients provided written informed consent Clinical trials registration: ‐ Sample size calculation: Quote: "The required number of patients in each group was estimated to be 115. Given a dropout rate of 10%, the target number of patients per group was set at 127, and the total number of patients in both groups combined was set at 254"